{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:09:31Z","timestamp":1770282571496,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1-3","license":[{"start":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T00:00:00Z","timestamp":1400630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12026-014-8547-7","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T13:05:56Z","timestamp":1400591156000},"page":"273-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid"],"prefix":"10.1007","volume":"59","author":[{"given":"K. A. N.","family":"Messingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Holahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,21]]},"reference":[{"key":"8547_CR1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.immunol.21.120601.141103","volume":"21","author":"HJ Gould","year":"2003","unstructured":"Gould HJ, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579\u2013628.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"8547_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","volume":"8","author":"HJ Gould","year":"2008","unstructured":"Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205\u201317.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"8547_CR3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1189\/jlb.0603275","volume":"75","author":"B Frossi","year":"2004","unstructured":"Frossi B, De Carli M, Pucillo C. The mast cell: an antenna of the microenvironment that directs the immune response. J Leukoc Biol. 2004;75(4):579\u201385.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"8547_CR4","first-page":"245","volume":"86C","author":"H Permin","year":"1978","unstructured":"Permin H, Wiik A. The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus. Acta Pathol Microbiol Scand C. 1978;86C(5):245\u20139.","journal-title":"Acta Pathol Microbiol Scand C"},{"issue":"2","key":"8547_CR5","first-page":"193","volume":"18","author":"TT Provost","year":"1974","unstructured":"Provost TT, Tomasi TB Jr. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol. 1974;18(2):193\u2013200.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"8547_CR6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clin.1996.4297","volume":"82","author":"J Guo","year":"1997","unstructured":"Guo J, Rapoport B, McLachlan SM. Thyroid peroxidase autoantibodies of IgE class in thyroid autoimmunity. Clin Immunol Immunopathol. 1997;82(2):157\u201362.","journal-title":"Clin Immunol Immunopathol"},{"issue":"10","key":"8547_CR7","first-page":"3602","volume":"84","author":"A Sato","year":"1999","unstructured":"Sato A, et al. A possible role of immunoglobulin E in patients with hyperthyroid Graves\u2019 disease. J Clin Endocrinol Metab. 1999;84(10):3602\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8547_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/03009740310004658","volume":"33","author":"I Sekigawa","year":"2004","unstructured":"Sekigawa I, et al. Possible importance of immunoglobulin E in foetal loss by mothers with anti-SSA antibody. Scand J Rheumatol. 2004;33(1):44\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"1\u20132","key":"8547_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2006.06.030","volume":"180","author":"DD Mikol","year":"2006","unstructured":"Mikol DD, et al. Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients. J Neuroimmunol. 2006;180(1\u20132):40\u20139.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"8547_CR10","doi-asserted-by":"crossref","first-page":"e90424","DOI":"10.1371\/journal.pone.0090424","volume":"9","author":"B Dema","year":"2014","unstructured":"Dema B, et al. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PLoS ONE. 2014;9(2):e90424.","journal-title":"PLoS ONE"},{"issue":"9","key":"8547_CR11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jama.1967.03120220053008","volume":"200","author":"RE Jordon","year":"1967","unstructured":"Jordon RE, et al. Basement zone antibodies in bullous pemphigoid. JAMA. 1967;200(9):751\u20136.","journal-title":"JAMA"},{"issue":"3","key":"8547_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1523-1747.ep12616580","volume":"99","author":"GJ Giudice","year":"1992","unstructured":"Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99(3):243\u201350.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"8547_CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197802232980803","volume":"298","author":"BU Wintroub","year":"1978","unstructured":"Wintroub BU, et al. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med. 1978;298(8):417\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"8547_CR14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/1523-1747.ep12505711","volume":"78","author":"AM Dvorak","year":"1982","unstructured":"Dvorak AM, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol. 1982;78(2):91\u2013101.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"8547_CR15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","volume":"120","author":"OG Dimson","year":"2003","unstructured":"Dimson OG, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120(5):784\u20138.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"8547_CR16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archderm.1974.01630090016003","volume":"110","author":"CE Arbesman","year":"1974","unstructured":"Arbesman CE, et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol. 1974;110(3):378\u201381.","journal-title":"Arch Dermatol"},{"issue":"1\u20132","key":"8547_CR17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","volume":"346","author":"KA Messingham","year":"2009","unstructured":"Messingham KA, et al. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods. 2009;346(1\u20132):18\u201325.","journal-title":"J Immunol Methods"},{"key":"8547_CR18","first-page":"804a","volume":"114","author":"MSW Bowszyc-Dmochowska","year":"2000","unstructured":"Bowszyc-Dmochowska MSW, Dmochowski M. Detection of IgG4 deposits using a single-step direct immunofluorescence on natrium chloride-separated skin and elevated levels of serum total IgE in active bullous pemphigoid. J Invest Dermatol. 2000;114:804a.","journal-title":"J Invest Dermatol"},{"key":"8547_CR19","doi-asserted-by":"crossref","unstructured":"Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy. 1999; 29 Suppl 3: 109\u2013112; discussion 113\u20135.","DOI":"10.1046\/j.1365-2222.1999.0290s3109.x"},{"issue":"4","key":"8547_CR20","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.4049\/jimmunol.130.4.1896","volume":"130","author":"MD Tharp","year":"1983","unstructured":"Tharp MD, Suvunrungsi RT, Sullivan TJ. IgE-mediated release of histamine from human cutaneous mast cells. J Immunol. 1983;130(4):1896\u2013901.","journal-title":"J Immunol"},{"issue":"2","key":"8547_CR21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174\u20138.","journal-title":"Arch Dermatol"},{"issue":"1","key":"8547_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0923-1811(00)00149-3","volume":"26","author":"Y Amo","year":"2001","unstructured":"Amo Y, et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2001;26(1):14\u20138.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"8547_CR23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","volume":"37","author":"Y Tsuji-Abe","year":"2005","unstructured":"Tsuji-Abe Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37(3):145\u20139.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"8547_CR24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","volume":"119","author":"S Hofmann","year":"2002","unstructured":"Hofmann S, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002;119(5):1065\u201373.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"8547_CR25","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","volume":"127","author":"JA Fairley","year":"2007","unstructured":"Fairley JA, et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice. J Invest Dermatol. 2007;127(11):2605\u201311.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"8547_CR26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2133.2000.03661.x","volume":"143","author":"S Christophoridis","year":"2000","unstructured":"Christophoridis S, et al. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol. 2000;143(2):349\u201355.","journal-title":"Br J Dermatol"},{"issue":"8","key":"8547_CR27","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.157.8.3642","volume":"157","author":"E Delaporte","year":"1996","unstructured":"Delaporte E, et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol. 1996;157(8):3642\u20137.","journal-title":"J Immunol"},{"issue":"4","key":"8547_CR28","first-page":"577","volume":"42","author":"R Dopp","year":"2000","unstructured":"Dopp R, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000;42(4):577\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8547_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","volume":"144","author":"Y Iwata","year":"2008","unstructured":"Iwata Y, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008;144(1):41\u20138.","journal-title":"Arch Dermatol"},{"issue":"2","key":"8547_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","volume":"49","author":"N Ishiura","year":"2008","unstructured":"Ishiura N, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49(2):153\u201361.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"8547_CR31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","volume":"127","author":"JJ Zone","year":"2007","unstructured":"Zone JJ, et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol. 2007;127(5):1167\u201374.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"8547_CR32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm1496","volume":"13","author":"W Nishie","year":"2007","unstructured":"Nishie W, et al. Humanization of autoantigen. Nat Med. 2007;13(3):378\u201383.","journal-title":"Nat Med"},{"issue":"5","key":"8547_CR33","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92(5):2480\u20138.","journal-title":"J Clin Invest"},{"issue":"4","key":"8547_CR34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","volume":"31","author":"Z Liu","year":"2008","unstructured":"Liu Z, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun. 2008;31(4):331\u20138.","journal-title":"J Autoimmun"},{"issue":"1","key":"8547_CR35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4049\/jimmunol.116.1.112","volume":"116","author":"T Baba","year":"1976","unstructured":"Baba T, et al. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol. 1976;116(1):112\u20136.","journal-title":"J Immunol"},{"issue":"7","key":"8547_CR36","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.4049\/jimmunol.169.7.3987","volume":"169","author":"R Chen","year":"2002","unstructured":"Chen R, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol. 2002;169(7):3987\u201392.","journal-title":"J Immunol"},{"issue":"4","key":"8547_CR37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","volume":"68","author":"P Valent","year":"2013","unstructured":"Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68(4):417\u201324.","journal-title":"Allergy"},{"issue":"5","key":"8547_CR38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.it.2004.03.005","volume":"25","author":"U Blank","year":"2004","unstructured":"Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol. 2004;25(5):266\u201373.","journal-title":"Trends Immunol"},{"key":"8547_CR39","first-page":"37","volume":"19","author":"F Bergh Van den","year":"2003","unstructured":"Van den Bergh F, Giudice GJ. BP180 (type XVII collagen) and its role in cutaneous biology and disease. Adv Dermatol. 2003;19:37\u201371.","journal-title":"Adv Dermatol"},{"issue":"35","key":"8547_CR40","doi-asserted-by":"crossref","first-page":"23386","DOI":"10.1074\/jbc.M109.034090","volume":"284","author":"CW Franzke","year":"2009","unstructured":"Franzke CW, Bruckner-Tuderman L, Blobel CP. Shedding of collagen XVII\/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem. 2009;284(35):23386\u201396.","journal-title":"J Biol Chem"},{"issue":"6454","key":"8547_CR41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/366421a0","volume":"366","author":"BJ Sutton","year":"1993","unstructured":"Sutton BJ, Gould HJ. The human IgE network. Nature. 1993;366(6454):421\u20138.","journal-title":"Nature"},{"issue":"1","key":"8547_CR42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.1001753","volume":"187","author":"KN Messingham","year":"2011","unstructured":"Messingham KN, et al. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol. 2011;187(1):553\u201360.","journal-title":"J Immunol"},{"issue":"1","key":"8547_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.1998.02028.x","volume":"138","author":"Y Kitajima","year":"1998","unstructured":"Kitajima Y, et al. Internalization of the 180\u00a0kDa bullous pemphigoid antigen as immune complexes in basal keratinocytes: an important early event in blister formation in bullous pemphigoid. Br J Dermatol. 1998;138(1):71\u20136.","journal-title":"Br J Dermatol"},{"issue":"5","key":"8547_CR44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","volume":"115","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol. 2000;115(5):842\u20138.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"8547_CR45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","volume":"129","author":"H Iwata","year":"2009","unstructured":"Iwata H, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol. 2009;129(4):919\u201326.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"8547_CR46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000246928","volume":"189","author":"Y Kitajima","year":"1994","unstructured":"Kitajima Y, et al. A possible cell-biologic mechanism involved in blister formation of bullous pemphigoid: anti-180-kD BPA antibody is an initiator. Dermatology. 1994;189(Suppl 1):46\u20139.","journal-title":"Dermatology"},{"issue":"5","key":"8547_CR47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","volume":"166","author":"C Dufour","year":"2012","unstructured":"Dufour C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140\u20132.","journal-title":"Br J Dermatol"},{"issue":"11","key":"8547_CR48","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","volume":"148","author":"VA London","year":"2012","unstructured":"London VA, et al. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241\u20133.","journal-title":"Arch Dermatol"},{"issue":"26","key":"8547_CR49","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","volume":"341","author":"H Milgrom","year":"1999","unstructured":"Milgrom H, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966\u201373.","journal-title":"N Engl J Med"},{"issue":"6","key":"8547_CR50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","volume":"170","author":"R Djukanovic","year":"2004","unstructured":"Djukanovic R, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8547_CR51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2222.2005.02191.x","volume":"35","author":"ST Holgate","year":"2005","unstructured":"Holgate ST, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408\u201316.","journal-title":"Clin Exp Allergy"},{"issue":"1\u20133","key":"8547_CR52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000237504","volume":"113","author":"DW MacGlashan Jr","year":"1997","unstructured":"MacGlashan DW Jr, et al. Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol. 1997;113(1\u20133):45\u20137.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"8547_CR53","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","volume":"112","author":"C Prussin","year":"2003","unstructured":"Prussin C, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8547_CR54","first-page":"2","volume":"11","author":"N Scheinfeld","year":"2005","unstructured":"Scheinfeld N. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J. 2005;11(1):2.","journal-title":"Dermatol Online J"},{"issue":"1","key":"8547_CR55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mai.2002.125488","volume":"110","author":"H Plewako","year":"2002","unstructured":"Plewako H, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110(1):68\u201371.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8547_CR56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","volume":"131","author":"O Noga","year":"2003","unstructured":"Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131(1):46\u201352.","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"8547_CR57","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","volume":"123","author":"JA Fairley","year":"2009","unstructured":"Fairley JA, et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"8547_CR58","unstructured":"Autoimmune disease: statistics. Retrieved March 15, 2014, from http:\/\/www.aarda.org ."},{"key":"8547_CR59","doi-asserted-by":"crossref","unstructured":"Yu KPD, Crew A, Messingham KAN, Fairley JA, Woodley DT. Successful omalizumab therapy for bullous pemphigoid patients. J Am Acad Dermatol. 2014 (in press).","DOI":"10.1016\/j.jaad.2014.04.053"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8547-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-014-8547-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8547-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:42:50Z","timestamp":1689234170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-014-8547-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,21]]},"references-count":59,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["8547"],"URL":"https:\/\/doi.org\/10.1007\/s12026-014-8547-7","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,21]]}}}